Marmoset Cytochrome P450 3A4 Ortholog Expressed in Liver and Small-Intestine Tissues Efficiently Metabolizes Midazolam, Alprazolam, Nifedipine, and Testosterone by Shotaro Uehara et al.
1521-009X/45/5/457–467$25.00 https://doi.org/10.1124/dmd.116.074898
DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 45:457–467, May 2017
Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics
Marmoset Cytochrome P450 3A4 Ortholog Expressed in Liver and
Small-Intestine Tissues Efficiently Metabolizes Midazolam,
Alprazolam, Nifedipine, and Testosterone
Shotaro Uehara,1 Yasuhiro Uno,1 Kazuyuki Nakanishi, Sakura Ishii, Takashi Inoue, Erika Sasaki,
and Hiroshi Yamazaki
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo, Japan (S.U., K.N., S.I.,
H.Y.); Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Wakayama, Japan (Y.U.);
Department of Applied Developmental Biology (T.I.), and Center of Applied Developmental Biology (E.S.), Central Institute for
Experimental Animals, Kawasaki, Japan; and Keio Advanced Research Center, Keio University, Minato-ku, Tokyo, Japan (E.S.)
Received December 29, 2016; accepted February 10, 2017
ABSTRACT
Commonmarmosets (Callithrix jacchus), small NewWorld primates,
are increasingly attracting attention as potentially useful animal
models for drug development. However, characterization of cyto-
chrome P450 (P450) 3A enzymes involved in the metabolism of a
wide variety of drugs has not investigated in marmosets. In this
study, sequence homology, tissue distribution, and enzymatic
properties of marmoset P450 3A4 ortholog, 3A5 ortholog, and 3A90
were investigated. Marmoset P450 3A forms exhibited high amino
acid sequence identities (88–90%) to the human and cynomolgus
monkey P450 3A orthologs and evolutionary closeness to human
and cynomolgus monkey P450 3A orthologs compared with other
P450 3A enzymes. Among the fivemarmoset tissues examined, P450
3A4 ortholog mRNA was abundant in livers and small intestines
where P450 3A4 ortholog proteins were immunologically detected.
Three marmoset P450 3A proteins heterologously expressed in
Escherichia coli membranes catalyzed midazolam 19- and
4-hydroxylation, alprazolam 4-hydroxylation, nifedipine oxidation,
and testosterone 6b-hydroxylation, similar to cynomolgus monkey
and human P450 3A enzymes. Among the marmoset P450 3A
enzymes, P450 3A4 ortholog effectively catalyzed midazolam
19-hydroxylation, comparable to microsomes from marmoset livers
and small intestines. Correlation analyses with 23 individual mar-
moset liver microsomes suggested contributions of P450 3A en-
zymes to 19-hydroxylation of bothmidazolam (humanP450 3Aprobe)
and bufuralol (human P450 2D6 probe), similar to cynomolgus
monkey P450 3A enzymes. These results indicated that marmoset
P450 3A forms had functional characteristics roughly similar to
cynomolgus monkeys and humans in terms of tissue expression
patterns and catalytic activities, suggesting marmosets as suitable
animal models for P450 3A–dependent drug metabolism.
Introduction
Common marmosets (Callithrix jacchus) have attracted increasing
attention as a potentially useful nonhuman primate model in fields such
as pharmacokinetics, toxicology, neuroscience, stem-cell research,
immunology, and infectious disease because of their genetic closeness
to humans, small body size (weighing 350–400 g on average), high
reproductive efficiency (typically producing twins), early sexual
maturity (reached within 18 months of age), and applicability of
transgenic technologies (Orsi et al., 2011; Sasaki, 2015). Cynomolgus
monkeys (Macaca fascicularis) are the widely used nonhuman primate
species for pharmacokinetics and drug-safety testing in pharmaceutical
companies.
Cytochrome P450s (P450s), the major drug-metabolizing enzymes
comprising multiple subfamilies, catalyze the oxidative biotransforma-
tion of potentially toxic compounds, including drugs and new chemical
compounds (Wrighton and Stevens, 1992). In humans, it has been
reported that approximately 75% of the drugs on the market are cleared
by P450s, and P450 3A enzymes are significantly involved in the
metabolism of more than 50% of the drugs (Williams et al., 2004). In
humans, the P450 3A subfamily consists of fourmembers: P450 3A4, 3A5,
3A7, and 3A43 forms. Human P450 3A enzymes reportedly metabolize
midazolam, alprazolam, nifedipine, and testosterone (Yamazaki et al.,
2002; Ohtsuka et al., 2010). P450 3A4 and 3A5 mRNAs are highly
expressed in livers, followed by small intestines (among 10 human tissues)
(Nishimura et al., 2003), and their protein expression was also detected in
livers (Yamazaki et al., 1995) and small intestines (Paine et al., 2006). P450
3A4protein expressionwas approximately 10-fold higher than that of P450
3A5 in human livers (Yamaori et al., 2004, 2005; Wang et al., 2008).
Marmoset P450 3A forms identified to date are P450 3A4 ortholog
(formerly 3A21), 3A5 ortholog, and 3A90 (http://drnelson.uthsc.edu/
CytochromeP450.html). Our previous study showed that marmoset
P450 3A4 ortholog and 3A90 enzymes effectively catalyzed midazolam
19-hydroxylation, similar to human and cynomolgus monkey P450 3As
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(Uehara et al., 2016a). Marmoset and cynomolgus monkey P450 3A4
ortholog also catalyzed omeprazole 5-hydroxylation and sulfoxidation
reactions with high capacity (Uehara et al., 2016b). Quantitative analysis
of gene expression for common marmoset transcriptomes indicated that
P450 3A4 ortholog and 3A5 ortholog/3A90 mRNAs were expressed in
livers and small intestines, similar to human P450 3A mRNA (Shimizu
et al., 2014). P450 3A4 and 3A5 ortholog-like proteins were detected in
marmoset livers (Schulz et al., 2001). Despite the potential importance as
a nonhuman primate model in drug-metabolism and toxicological
research, the molecular characteristics of marmoset P450 3A forms
has not been analyzed in detail.
More than 20 marmoset P450 cDNAs have been identified so far;
these P450s have high sequence similarities (.85%) to their ortholo-
gous human P450s (Uno et al., 2016). Overall, substrate specificity and
tissue expression of orthologous P450 enzymes are similar between
marmosets and humans, except for some enzymes belonging to the P450
2 family. In this study, gene cluster organization, sequence similarity,
tissue distribution, and enzymatic properties of marmoset P450 3A4
ortholog, 3A5 ortholog, and 3A90 were investigated. This work is of
importance for understanding themetabolic characteristics of marmosets
as animal models in drug development.
Materials and Methods
Chemicals and Enzymes. Alprazolam, midazolam, and testosterone were
purchased fromWako Pure Chemicals (Osaka, Japan). 4-Hydroxyalprazolamwas
purchased from Enzo Life Sciences (Farmingdale, NY). Nifedipine, oxidized
nifedipine, 19-hydroxymidazolam, 4-hydroxymidazolam, and 6b-hydroxytestosterone
were purchased from Sigma-Aldrich (Tokyo, Japan). Bufuralol and 19-hydroxybufuralol
were purchased from Toronto Research Chemicals (Toronto, Canada). Oligonucleo-
tides were synthesized at Sigma Genosys (Ishikari, Japan). Pooled liver microsomes
from marmosets (five males, sexually mature) and humans (74 males and 76 females,
18–82 years old) were purchased from Corning Life Sciences (Woburn, MA). Pooled
liver microsomes from cynomolgus monkeys (eight males, 3–8 years old) and pooled
intestine microsomes from cynomolgus monkeys (15 males, 2–5 years old) and
humans (four males and six females, 14–65 years old) were purchased fromXenotech
(Lenexa, KS). Pooledmicrosomes of brains, lungs, livers, kidneys, and small intestines
were prepared from tissue samples of 20 marmosets (10 males and 10 females, .2
years old) raised at the Central Institution for Experimental Animals (Kawasaki, Japan)
as described previously (Uehara et al., 2016c). Individual liver microsomes were
prepared from23marmosets (14males and nine females,.2years old). This studywas
reviewed and approved by the Institutional Animal Care and Use Committee (Central
Institution for Experimental Animals). Anti-human P450 3A4 antibodies (WB-3A4)
and anti-human P450 3A5 antibodies (WB-3A5) were purchased from Corning Life
Sciences. Anti-human P450 2D6 antibodies were purchased from Nosan Corporation
(Yokohama, Japan). Anti-human protein disulfide isomerase antibodies (H-160) and
goat anti-rabbit IgG-horseradish peroxidase were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). All other regents used were the highest quality
commercially available.
Bioinformatics. The structure of the marmoset P450 3A gene cluster was
analyzed by BLAT (UCSC Genome Bioinformatics, University of California,
Santa Cruz, CA) and byGGGenome (DNAData Bank of Japan, National Institute
of Genetics, Mishima, Japan). The amino acid sequence similarity of marmoset
P450 3A forms compared with other species P450 3A members was determined
by BLAST (National Center for Biotechnology Information, Bethesda, MD). The
amino acid sequence alignment was performed using the Genetyx system
(Software Development, Tokyo, Japan). The phylogenetic tree was constructed
with the aligned sequences by the neighbor-joining method using DNASIS Pro
(Hitachi Software, Tokyo, Japan). P450 amino acid sequences used were from
GenBank: human P450 3A4 (NP_059488), 3A5 (NP_000768), 3A7
(NP_000756), 3A43 (NP_073731), and 2D6 (NP_000097); chimpanzee P450
3A4 (NP_001116247), 3A5 (NP_001087246), and 3A7 (NP_001087243);
orangutan P450 3A43 (ABU85093) and 3A67 (ABU85096); cynomolgusmonkey
P450 3A4 (NP_001271463), 3A5 (NP_001306440), 3A7 (NP_001306436), and
3A43 (NP_001306434); rhesus monkey P450 3A4 (NP_001035504), 3A5
(NP_001035309), and 3A7 (NP_001182687); marmoset P450 3A4 ortholog
(NP_001191369), 3A5 ortholog (NP_001191371), and 3A90 (NP_001191372);
dog P450 3A12 (NP_001003340) and 3A26 (NP_001003338); pig P450 3A22
(NP_001182438), 3A29 (NP_999588), 3A39 (NP_999587), and 3A46
(NP_001128296); rabbit P450 3A6 (NP_001164739); guinea pig P450 3A14
(NP_001166587), 3A15 (NP_001166588), and 3A17 (NP_001166540); rat P450
3A2 (NP_695224), 3A9 (NP_671739), 3A18 (NP_665725), 3A23 (NP_037237), and
3A62 (NP_001019403); and mouse P450 3A11 (NP_031844), 3A13 (NP_031845),
3A16 (NP_031846), 3A25 (NP_062766), 3A41 (NP_001098629), 3A44
(NP_796354), 3A57 (NP_001093650), and 3A59 (NP_001098630).
Quantitative Reverse-Transcription Polymerase Chain Reaction. The
P450 3A mRNA distribution in marmoset tissues was analyzed by real-time
reverse-transcription (RT) polymerase chain reaction (PCR) as described
previously (Uehara et al., 2016d). In brief, total RNAs were extracted from
brains, lungs, livers, kidneys, and small intestines, each pooled from 12 adult
marmosets (six males and six females,.2 years old), using an RNeasy Mini Kit
(Qiagen, Valencia, CA) and were used to synthesize cDNA using SuperScript III
RT reverse transcriptase (Invitrogen, Carlsbad, CA) with random hexamers in a
20-ml reaction. Quantitative RT-PCR was performed with a SYBR Green–based
detection system using gene-specific primers: 59-GCTTTTGGAAGTTTGA-
CATGGA-39 and 59-CAGGCTGTCGACCATCATAAATC-39 for marmoset
P450 3A4 ortholog, 59- GTGAAGAAGTTCCTAAAATTTGATTTCC-39 and
59- GGGGTAAGGAACGGGAAGAA-39 for marmoset P450 3A5 ortholog, and
59- CCTAAAATTTGATGTATTAGCTCCACTG-39 and 59- GGATAAG-
GAACGGAAAGAGTACTACTGA-39 for marmoset P450 3A90. The reaction
mixture contained 400 nM each primer, 12.5 ml of Power SYBR Green PCR
Master Mix (Applied Biosystems, Foster City, CA), and 2 ml of template DNA in
a total volume of 25 ml. The PCR conditions were as follows: an initial
denaturation for 10minutes at 95C, followed by 40 cycles of 95C for 15 seconds
and 60C for 1 minute. Real-time PCR was performed with an ABI PRISM
7300 sequence detection system (Applied Biosystems). This study performed
absolute quantification, displaying high PCR efficiency (.93%) comparable for
three P450 genes with a high correlation coefficient (r . 0.99). Standard curves
were created by absolute amounts (102–106 copies) with a 10-fold dilution series
of purified PCR products of marmoset P450 3A cDNAs. The expression level of
each P450 3A mRNA was normalized to the level of 18S ribosomal RNA
measured using Eukaryotic 18S ribosomal RNA Endogenous Control (Applied
Biosystems).
Heterologous Protein Expression in Escherichia coli. Marmoset P450 3A4
ortholog, 3A5 ortholog, and 3A90 cDNAs were cloned from liver by RT-PCR as
described previously (Uehara et al., 2015c). To enhance the efficiency of
Fig. 1. P450 3A cluster in marmosets, cynomolgus monkeys, and humans. The
structure of the P450 3A gene cluster in marmoset, cynomolgus monkey, and human
genome was analyzed by BLAT. Three marmoset P450 3A genes were located
adjacent to ZSCAN25 and TRIM4 in the genome region corresponding to human and
cynomolgus P450 3A genes. This schematic diagram is not proportionate to actual
size and distance on the chromosome.
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expression for recombinant marmoset P450 3A proteins, the N-terminal
modification was performed for the expression plasmids constructed with the
P450 3A cDNAs by PCR using the following forward and reverse primers:
cjCYP3A4 (5exp1) 59-CATATGGCTCTGTTATTAGCAGTTTTCCTGG-
TGCTTCTGTATCTA-39 and cjCYP3A4 (3exp1) 59-TCTAGATTAGGCTC-
CACTTACAGTCC-39 for marmoset P450 3A4 ortholog, cjCYP3A5 (5exp1)
Fig. 2. Multiple alignment of P450 3A amino acid sequences from marmosets, cynomolgus monkeys, and humans. P450 3A amino acid sequences from marmosets,
cynomolgus monkeys, and humans were aligned using Genetyx. Asterisks and dots under amino acid alignment indicate regions conserved and roughly conserved among the
three species, respectively. Solid and broken lines indicate substrate recognition sites and heme-binding domain, respectively.
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59-CATATGGCTAAGAAAACGAGCTCTAAAGGTAAGCTTATTCCAGGA-
CCCGCACCT-39 and cjCYP3A5 (3exp1) 59-TCTAGATTATTCTCCACTTAGGG-
TTC-39 for marmoset P450 3A5 ortholog, and cjCYP3A4 (5exp1) 59-
CATATGGCTCTGTTATTAGCAGTTTTCCTGGTGCTTCTGTATCTA-
39 and cjCYP3A5 (3exp1) 59-TCTAGATTATTCTCCACTTAGGGTTC-
39 for marmoset P450 3A90. PCR amplification was carried out for 30 cycles
(denaturation at 98C for 15 seconds, annealing at 60C for 30 seconds, and
extension at 68C for 2minutes) using KOD-Plus-NeoDNA polymerase (Toyobo,
Osaka, Japan) with an ABI GeneAmp PCR System 2720 thermocycler (Applied
Biosystems). PCR products were cloned into pGEM-T easy vectors (Promega,
Madison, WI) and subsequently subcloned into pCW vectors using the restriction
sites of the NdeI and XbaI sites (underlined). Recombinant P450 3A proteins were
prepared in an Escherichia coli DH5a expression system, and the concentra-
tion of P450 and NADPH-P450 reductase in each membrane preparation was
measured as described previously (Yamazaki et al., 2002). Recombinant proteins
were produced on the yield of approximately 2 mM culture medium. Recombinant
marmoset P450 2D6 and 2D8; recombinant cynomolgus monkey 3A4 and 3A5;
and recombinant human P450 3A4, 3A5, and 2D6 were prepared as described
previously (Yamazaki et al., 2002; Uno et al., 2010; Uehara et al., 2015a).
Western Blotting. Recombinant P450 proteins (1.0 pmol) or livermicrosomes
(10 mg) were subjected to 10% sodium dodecyl sulfate polyacrylamide gel
electrophoresis, and then electrophoretically transferred to a polyvinylidene
difluoride membrane (MerckMillipore, Billerica, MA). After blocking with 0.5%
nonfat milk in Tris-buffered saline (50 mM Tris, 138 mM NaCl, 2.7 mM KCl)
containing 0.05% Tween 20 (v/v) at room temperature for 30 minutes, the
membrane was probed with anti-human P450 3A4 antibodies (1:2000), anti-
human P450 3A5 antibodies (1:5000), anti-human P450 2D6 antibodies (1:
10,000), or anti-human protein disulfide isomerase antibodies (1:200) at room
temperature for 1 hour, and then with goat-anti-rabbit IgG antibodies (1:5000) at
room temperature for 20 minutes. The antigen-antibody complex was visualized
by an ECL Prime Western Blotting Detection System (GE Healthcare,
Buckinghamshire, UK).
Enzyme Assay. Midazolam 19- and 4-hydroxylation, nifedipine oxidation,
testosterone 6b-hydroxylation, and bufuralol 19-hydroxylation activities by
recombinant P450 proteins and tissue microsomes were measured as described
previously (Yamazaki et al., 2002; Uehara et al., 2015b). For alprazolam
hydroxylation, the incubation mixture consisted of 40 pmol/ml recombinant
protein or 0.5 mg/ml microsomes (liver or small intestine), 200 mM alprazolam,
an NADPH-generating system (0.25 mM NADP+, 2.5 mM glucose 6-phosphate,
and 0.25 units/ml glucose 6-phosphate dehydrogenase), and 100 mM potassium
phosphate buffer (pH 7.4) in a total volume of 0.25 ml. Reactions were started by
adding the NADPH-generating system, and were performed with 100 rpm/min of
shaking at 37C for 10 minutes. Reactions were terminated by the addition of
methanol (0.40 ml), and then centrifuged at 20,000g for 10 minutes. The resulting
supernatant was analyzed by reversed-phase high-performance liquid chroma-
tography (HPLC) using a Prominence-I LC-2030C HPLC system with a fluores-
cence detector (Shimadzu, Kyoto, Japan). HPLC analysis was performed on a C18
column (L-column2ODS, 5mm, 150 4.6mm;Chemicals Evaluation andResearch
Institute, Tokyo, Japan) using isocratic elution by methanol/acetonitrile/10 mM
potassium phosphate buffer (pH 7.4) (24:33:43, v/v/v) at a flow rate of 1.0 ml/min
with monitoring of the absorbance at 220 nm. Metabolite concentrations were
quantified based on standard curves prepared with reference standards. Kinetic
parameters for midazolam 19- and 4-hydroxylation and nifedipine oxidation were
estimated from the fitted curves using Michaelis-Menten equations, substrate
inhibition equations, or Hill equations (Emoto et al., 2001; Shimizu, et al., 2007;
Okada, et al., 2009) using the KaleidaGraph program (Synergy Software,
Reading, PA). Linear regression analysis was performed with Prism (Graphpad
Software, La Jolla, CA).
Results
Determination of P450 3A Gene Cluster Structure and Amino
Acid Sequence Identity in Marmosets. The structure of the marmoset
P450 3A gene cluster was determined using marmoset genomic
sequence by BLAT. The marmoset P450 3A cluster was localized in
marmoset chromosome 2 (12,136,811–12,255,660) (Fig. 1). Three
marmoset P450 3A genes (P450 3A4 ortholog, 3A5 ortholog, and
3A90) form a cluster with a total length of 118,850 bp (containing
two gaps) between ZSCAN25 and TRIM4 genes on the short arm of
chromosome 2. No marmoset P450 3A genes had a one-to-one
orthologous relationship to human or cynomolgus monkey P450 3A
genes. A marmoset P450 3A43 ortholog was not found in the genome as
analyzed by BLAT or GGGenome. The amino acid sequences of
marmoset P450 3A4 ortholog, 3A5 ortholog, and 3A90 had six substrate
recognition sites and a heme-binding site, similar to human and
cynomolgus monkey P450 3A forms (Fig. 2). Amino acid sequences
of marmoset P450 3A4 ortholog, 3A5 ortholog, and 3A90 showed high
degrees of sequence identity (.88%) to those of human and cynomolgus
monkey P450 3A forms (Table 1). Phylogenetic analysis using amino
acid sequences of the P450 3A forms from 12 species showed that
marmoset P450 3A forms were evolutionarily closer to the P450 3A
forms of primates, including humans, chimpanzees, orangutans, rhesus
monkeys, and cynomolgus monkeys, than those of dogs, pigs, guinea
pigs, rats, and mice (Fig. 3).
TABLE 1
Similarity of amino acid sequences of three marmoset P450 3A forms compared
with P450 3As from other species
P450 Form
Marmoset P450
3A4 Ortholog 3A5 Ortholog 3A90
Human
3A4 90 83 82
3A5 84 89 88
3A7 86 79 78
3A43 76 73 74
Chimpanzee
3A4 90 83 82
3A5 85 89 88
3A7 87 80 79
Orangutan
3A67 87 80 80
3A43 76 74 74
Cynomolgus monkey
3A4 90 82 81
3A5 83 89 88
3A7 87 79 79
3A43 76 73 74
Dog
3A12 78 77 77
3A26 76 75 75
Pig
3A22 75 73 73
3A29 75 75 73
3A39 74 75 73
3A46 75 74 72
Rabbit
3A6 75 75 74
Rat
3A2 71 70 70
3A9 77 76 75
3A18 69 69 68
3A23 71 72 71
3A62 71 72 71
Mouse
3A11 73 73 72
3A13 75 75 74
3A16 69 69 69
3A25 71 70 69
3A41 70 71 70
3A44 69 69 69
3A57 69 67 67
3A59 70 69 68
Marmoset
3A4 ortholog – 84 82
3A5 ortholog 84 – 96
3A90 82 96 –
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Tissue Distribution of Three P450 3A mRNAs and Proteins in
Marmosets. Expression levels of marmoset P450 3AmRNAs in brains,
lungs, livers, kidneys, and small intestines were analyzed by real-time
RT-PCR. All three marmoset P450 3A mRNAs were abundantly
expressed in livers and small intestines among the five tissues examined
(Fig. 4). The expression level of P450 3A4 orthologmRNAwas.5-fold
(livers) and .3-fold (small intestines) higher than those of P450 3A5
ortholog and 3A90 mRNAs, respectively, indicating that P450 3A4
ortholog was the major P450 3A form in livers and small intestines, the
organs responsible for drug metabolism. P450 3A5 ortholog mRNA
was .7-fold higher in small intestines than livers, different from
P450 3A4 ortholog and 3A90 mRNAs expressed in these tissues at
comparable levels. Tissue distribution of P450 3A proteins in marmosets
was investigated by Western blotting using anti-human P450 3A4 and
3A5 antibodies capable of detecting selectively recombinant marmoset
P450 3A proteins (Fig. 5A). P450 3A4 ortholog and 3A5 ortholog/3A90
proteins were detected in marmoset livers and small intestines (Fig. 5B);
abundant P450 3A4 ortholog protein was detected in marmoset livers.
P450 3A4 ortholog and 3A5 ortholog/3A90 proteins were constitutively
expressed in livers from five individual marmosets (Fig. 5C).
Enzymatic Activities of Marmoset P450 3A Proteins. To assess
the enzymatic function of marmoset P450 3A enzymes, drug oxidation
activities by recombinant P450 3A proteins and tissue microsomes were
measured using typical human P450 3A probe substrates (midazolam,
Fig. 3. A phylogenetic tree of P450 3A amino acid sequences in various species. Phylogenetic analysis was performed using P450 3A amino acid sequences of marmoset
(cj), human (h), chimpanzee (chim), orangutan (ora), cynomolgus monkey (mf), rhesus monkey (mm), dog (d), pig (p), rabbit (rab), guinea pig (cp), rat (r), and mouse (m) by
the neighbor-joining method. Human P450 2D6 was used as an outgroup. Three marmoset P450 3A forms are shown in bold. The scale bar indicates the evolutionary
distance of 0.1 amino acid substitutions per site.
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alprazolam, nifedipine, and testosterone). Liver and small intestine micro-
somes from marmosets catalyzed midazolam 19- and 4-hydroxylation,
alprazolam 4-hydroxylation, nifedipine oxidation, and testosterone 6b-
hydroxylation in a manner similar to those of humans and cynomolgus
monkeys (Table 2); liver microsomes from marmoset and cynomolgus
monkeys catalyzed these reactions more strongly compared with those
from humans. All marmoset P450 3A4 ortholog, 3A5 ortholog, and 3A90
enzymes also metabolized above typical human P450 3A probe
substrates. Catalytic activities of the P450 3A4 ortholog enzyme were
the highest among the marmoset P450 3A enzymes analyzed. Bufuralol
19-hydroxylation activities, a typical human P450 2D probe activity, were
higher for marmoset P450 3A4 ortholog, 3A5 ortholog, and 3A90 than
human P450 3A4 and 3A5, similar to cynomolgus monkey P450 3A4
and 3A5 reported previously (Emoto et al., 2011). Kinetic analyses
indicated that marmoset liver microsomes more effectively catalyzed
midazolam 19-hydroxylation (Vmax/Km, 0.74 ml/min/mg protein) with
substrate inhibition kinetic, compared with those of humans and
cynomolgus monkeys (Vmax/Km, 0.38 and 0.33 ml/min/mg protein,
respectively) (Fig. 6; Table 3). Marmoset P450 3A4 ortholog enzyme
was the most effective catalytic enzyme (Vmax/Km, 14 ml/min/nmol) for
midazolam 19-hydroxylation with substrate inhibition kinetic among
the marmoset, cynomolgus monkey, and human P450 3A enzymes, and
showed a low Km value (2.5 mM) comparable to liver microsomes
(8.1 mM) and small intestine microsomes (6.6 mM) from marmosets.
Similarly, kinetic analyses indicated that marmoset liver microsomes
effectively catalyzed nifedipine oxidation (Vmax/Km, 0.24 ml/min/mg
protein) comparable to those from humans and cynomolgus monkeys
(Vmax/Km, 0.25 and 0.35 ml/min/mg protein, respectively) (Fig. 6;
Table 4). Marmoset P450 3A4 ortholog enzyme also had a high Vmax/Km
(2.3 ml/min/nmol) for nifedipine oxidation and showed a low Km value
(33 mM), roughly corresponding to those of liver microsomes (42 mM)
and small intestine microsomes (84 mM) from marmosets. Vmax/Km
values of marmoset P450 3A5 ortholog and 3A90 enzymes for
midazolam 19- and 4-hydroxylation and nifedipine oxidation were of
different orders of magnitude compared with that of marmoset P450 3A4
ortholog.
Midazolam 19-hydroxylation activities were significantly correlated
with P450 3A4 ortholog contents (r = 0.76, p , 0.05; Fig. 7B), but not
with P450 3A5 ortholog/3A90 contents (r = 0.23) in 23 individual
marmoset liver microsomes (Fig. 7C). P450 3A4 ortholog, 3A5
ortholog/3A90, and sum of P450 3A contents in individual marmoset
liver microsomes were 77–218 (average 6 S.D., 150 6 45), 42–112
Fig. 4. Tissue distribution of P450 3A mRNAs in five marmoset tissues. Expression
levels of marmoset P450 3A4 ortholog, 3A5 ortholog, and 3A90 mRNAs were
normalized to 18S ribosomal RNA levels in each tissue (a pool of 12 marmosets, six
males and six females). For graphical presentation, P450 3A4 ortholog mRNA level
was adjusted to 1, and the relative expression levels of other P450 3A mRNAs to
P450 3A4 ortholog mRNA are shown. Data are the mean 6 standard deviation
values of triplicate determinations.
Fig. 5. Immunoblots of marmoset P450 3A proteins in marmoset tissues. (A)
Recombinant marmoset P450 3A proteins (1.0 pmol) were selectively detected by
immunoblotting using anti-human P450 3A4 and 3A5 antibodies. Expression levels
of P450 3A proteins in marmoset tissue microsomes (10 mg) (B) and individual liver
microsomes (lanes 1, 2, and 5, males; lanes 3 and 4, females) (C) were investigated.
Protein disulfide isomerase (PDI) was used as a loading control.
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(average 6 S.D., 83 6 18), and 137–321 (average 6 S.D., 233 6 57)
pmol/mg protein, respectively. The total contribution of P450 3A4 to
P450 3A protein was assumed to be 64 6 7% (range 51–74%). These
results indicated that P450 3A4 ortholog was the major hepatic P450 3A
enzyme in marmosets, similar to humans (Westlind-Johnsson et al.,
2003). Hydroxylation activities of midazolam and bufuralol were also
observed (Fig. 7D). Moreover, bufuralol 19-hydroxylation activities in
marmoset liver microsomes were correlated with midazolam 19-
hydroxylation activities (r = 0.81, p , 0.01; Fig. 7D), marmoset P450
2D contents (r = 0.50, p, 0.05; Fig. 7E), and sum of P450 3A contents
(r = 0.83, p , 0.01; Fig. 7F), although bufuralol 19-hydroxylation by
cDNA-expressed marmoset P450 3As was lower than cDNA-expressed
marmoset P450 2D6 (amajor hepatic P450 2D enzyme) (Table 2).When
considered together with high levels of P450 3A proteins in livers, P450
3A enzymes might play another important role for bufuralol 19-
hydroxylation by marmoset livers.
Discussion
In marmosets, three P450 3A genes have been identified (Qiu et al.,
2008); however, the molecular characteristics have not been clarified. In
this study, we investigated the sequence identity, tissue distribution, and
enzymatic function of marmoset P450 3A forms. Marmoset P450 3A
forms were highly identical (.88%) to the human and cynomolgus
monkey P450 3A orthologs (Table 1). A phylogenetic tree created using
amino acid sequences showed that marmoset P450 3A forms were
clustered with P450 3A forms from other primates, different from P450
3A forms found in preclinical animal species, including dogs, pigs, and
rodents (Fig. 3). The high similarity of P450 3A amino acid sequences
between marmosets, cynomolgus monkeys, and humans suggested a
possibility that the enzymatic function of P450 3A was conserved
among these primate species.
Among the marmoset P450 3A enzymes, P450 3A4 ortholog most
abundantly expressed in livers and small intestines effectively catalyzed
the oxidation of midazolam and nifedipine (Tables 3 and 4), and showed
a significant correlation between P450 3A4 ortholog contents and
midazolam 19-hydroxylation activities in 23 individual marmoset liver
microsomes (r = 0.76, p , 0.05; Fig. 7B), suggesting that P450 3A4
ortholog was the major catalyst for P450 3A–dependent drug metabo-
lism in livers and small intestines. Moreover, Km, Vmax, and Vmax/Km
values for the oxidation of midazolam and nifedipine were similar
between marmoset, cynomolgus monkey, and human P450 3A4
enzymes. By analysis of site-directed mutagenesis based on a three-
dimensional homology model of human P450 3A4, Phe-108, Ser-119,
Ile-120, Leu-211, Asp-214, Ile-301, Phe-304, Ala-305, Thr-309, Ala-
370, and Leu-373 were identified as key residues for substrate binding
and regioselectivity (He et al., 1997; Fowler et al., 2000, 2002; Khan
et al., 2002). These amino acid residues on human P450 3A4 were
completely shared with marmoset and cynomolgus monkey P450 3A4
ortholog, suggesting that the enzymatic function of P450 3A4 ortholog
enzyme was highly conserved between marmosets, cynomolgus mon-
keys, and humans. Therefore, marmosets might be a suitable model for
evaluating the P450 3A–dependent drug metabolism in preclinical
studies.
Oxidation of bufuralol, a typical human P450 2D probe, was faster in
marmoset livers than human livers (Table 2). Bufuralol 19-hydroxylation
activities were also higher for marmoset P450 3A enzymes than human
P450 3A enzymes, although those activities by marmoset P450 2D6
enzymes (major P450 2D enzyme responsible for bufuralol 19-
hydroxylation in marmoset liver in terms of expression level and
enzyme kinetics) were comparable to human P450 2D6 (Uehara et al.,
2015a). Correlation analyses with 23 individual marmoset liver
microsomes (Fig. 7) suggested contributions of P450 3A enzymes to
19-hydroxylation of midazolam (human P450 3A probe) and bufuralol
(human P450 2D6 probe). Similarly, cynomolgus monkey P450 3A4
and/or 3A5 enzymes were faster than human P450 3A enzymes in
bufuralol 19-hydroxylation and dextromethorphan O-dealkylation
(Emoto et al., 2011; Selvakumar et al., 2014). Hence, P450 3A enzymes
might account for the higher velocity of bufuralol 19-hydroxylation in
marmoset and cynomolgus monkey livers.
TABLE 2
Drug-metabolizing activities by recombinant P450 enzymes and tissue microsomes from marmosets, cynomolgus monkeys, and humans
Units of drug oxidation rates by tissue microsomes and recombinant P450 proteins are nmol/min/mg protein and nmol/min/nmol of P450, respectively. Each activity was measured at a substrate


















Marmoset liver 3.6 6 0.2 0.35 6 0.03 0.11 6 0.01 3.3 6 0.2 1.6 6 0.1 0.72 6 0.02 —
Cynomolgus monkey liver 1.9 6 0.1 0.49 6 0.01 0.058 6 0.002 3.8 6 0.2 1.8 6 0.3 — 1.7
Human liver 1.5 6 0.1 0.13 6 0.01 0.016 6 0.002 2.2 6 0.1 0.99 6 0.01 0.24 6 0.01 0.21
Marmoset small intestine 0.95 6 0.02 0.075 6 0.004 0.0080 6 0.0001 0.32 6 0.03 0.15 6 0.02 — —
Cynomolgus monkey
small intestine
1.2 6 0.1 0.29 6 0.01 0.015 6 0.001 1.1 6 0.1 0.47 6 0.01 — —
Human small intestine 0.77 6 0.01 0.082 6 0.005 0.0085 6 0.0002 1.2 6 0.1 0.58 6 0.01 — —
Recombinant P450
Marmoset 3A4 ortholog 29 6 1 9.1 6 0.6 1.4 6 0.1 25 6 1 58 6 2 1.9 6 0.2 —
Marmoset 3A5 ortholog 1.2 6 0.1 0.051 6 0.015 0.022 6 0.005 1.1 6 0.2 5.4 6 0.3 1.4 6 0.1 —
Marmoset 3A90 3.4 6 0.4 0.11 6 0.01 0.054 6 0.006 2.8 6 0.1 4.9 6 0.7 0.81 6 0.01 —
Marmoset 2D6 — — — — — 8.5 6 0.9 —
Marmoset 2D8 — — — — — 1.9 6 0.3 —
Cynomolgus monkey 3A4 18 6 1 15 6 1 1.5 6 0.1 33 6 3 50 6 2 — 0.99
Cynomolgus monkey 3A5 36 6 1 2.7 6 0.3 0.78 6 0.01 34 6 2 60 6 2 — 2.4
Cynomolgus monkey 2D6 — — — — — — 8.9
Cynomolgus monkey 2D44 — — — — — — 4.9
Human 3A4 11 6 1 2.3 6 0.1 0.74 6 0.02 22 6 2 20 6 1 0.13 6 0.01 0.41
Human 3A5 36 6 2 1.4 6 0.1 0.46 6 0.01 7.8 6 0.4 19 6 1 0.24 6 0.01 0.33
Human 2D6 — — — — — 5.8 6 0.7 6.1
aEnzymatic activities for bufuralol 19-hydroxylation by liver microsomes and recombinant P450 2D and 3A proteins at a substrate concentration of 200 mM are taken from Emoto et al. (2011).
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In addition to drugs, P450 enzymes have various important physio-
logic functions, including the metabolism of steroids, bile acids,
vitamins, and prostaglandins (Nebert and Dalton, 2006). In humans,
P450 3A4 plays major roles in testosterone 16b-, 6b-, and 2b-
hydroxylation and progesterone 16a-, 6b-, and 2b-hydroxylation
(Yamazaki and Shimada, 1997; Niwa et al., 2015). Progesterone
metabolism in humans is most similar to that in cynomolgus monkeys
and least similar to that in rats (Swinney, 1990). In this study, P450 3A4
ortholog, 3A5 ortholog, and 3A90 enzymes catalyzed testosterone 6b-
hydroxylation, similar to human P450 3A enzymes (Table 2). To
understand the physiologic similarity between marmosets and humans,
further study is needed to investigate the role of P450 enzymes in the
metabolism of various endogenous compounds.
In humans, P450 3A4 and 3A5 mRNAs are abundant in livers and
small intestines among the 10 human tissues (Nishimura et al., 2003),
and these proteins are expressed in human livers and small intestines
(Gibbs et al., 1999; Paine et al., 2006). Marmoset P450 3A4 ortholog,
3A5 ortholog, and 3A90 mRNAs and proteins were also expressed in
livers and small intestines among the five tissues (Figs. 4 and 5),
suggesting a possibility that the basal transcriptional regulation of P450
Fig. 6. Enzyme kinetics for midazolam hydroxylation and nifedipine
oxidation by recombinant marmoset, cynomolgus monkey, and human
P450 3A enzymes and liver and small intestine microsomes from
marmosets, cynomolgus monkeys, and humans. Kinetic analyses were
performed for midazolam 19- (closed) and 4-hydroxylation (open) and
nifedipine oxidation by liver (A and B) and small intestine (C and D)
microsomes from marmosets (triangles), cynomolgus monkeys
(squares), and humans (circles). Kinetic analyses were performed for
19- (closed) and 4-midazolam hydroxylation (open) and nifedipine
oxidation by recombinant P450 3A of marmosets (E and F) (P450 3A4
ortholog, circles; P450 3A5 ortholog, squares; P450 3A90, triangles),
cynomolgus monkeys (G and H) (P450 3A4, circles; P450 3A5,
squares), and humans (I and J) (P450 3A4, circles; P450 3A5,
squares).
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3A genes was shared between marmosets and humans. Indeed, the
sequences of the proximal promoter and the xenobiotic-responsive
enhancer module of the marmoset P450 3A4 ortholog gene are highly
identical (88%) to those of the human P450 3A4 gene (Koehler et al.,
2006). Several putative transcriptional factor-binding sites conserved
between marmoset P450 3A4 ortholog and human P450 3A4 promoter,
including the CCAAT/enhancer-binding protein binding site in the
proximal promoter and hepatic nuclear factor-4 binding site in the
xenobiotic-responsive enhancer module, might play an important role in
basal transcriptional regulation. The similarity of tissue expression
patterns possibly accounted for by common transcriptional regulation in
P450 3A genes suggests that themarmoset, again, would potentially be a
suitable model for preclinical safety testing in relation to P450 3A
enzymes.
The marmoset P450 3A cluster contained two genes highly identical
to human P450 3A5 genes, P450 3A5 ortholog and 3A90 (Fig. 1). By
phylogenomics analysis of primate P450 3A locus structure, marmoset
P450 3A4 ortholog shared a common ancestry with catarrhineP450 3A4,
whereas marmoset P450 3A5 ortholog and 3A90 shared a common
ancestry with catarrhine P450 3A5, suggesting that P450 3A5 expanded
in only New World monkeys, in contrast to the repeated duplication of
P450 3A4-like genes (P450 3A4, 3A7, and 3A67) in catarrhines (Qiu
et al., 2008). In comparison with the recombinant marmoset P450 3A4
ortholog, recombinant marmoset 3A5 ortholog and 3A90 moderately
metabolized multiple typical human P450 3A probe substrates, such as
midazolam, alprazolam, nifedipine, and testosterone (Table 2). It would
be of great interest to compare the physiologic significance of P450 3A5
ortholog and 3A90 with that of P450 3A4 ortholog in marmosets by
exhaustive analysis of substrate specificity using xenobiotics and
endogenous compounds.
In conclusion, amino acid sequences of three marmoset P450 3A
forms showed high sequence identities (.87%) with P450 3A forms of
TABLE 3
Kinetic parameters of midazolam 19- and 4-hydroxylation by recombinant P450 3A enzymes and tissue microsomes from marmosets, cynomolgus monkeys, and humans
Kinetic parameters were determined by nonlinear regression analysis (mean 6 standard error, n = 17 points of substrate concentrations of 0.5–625 mM) using the equation v = Vmax  [S]/(Km + [S])
for Michaelis-Menten or v = Vmax  [S]/(Km + [S] + [S]2/Ks) for substrate inhibition (Shimizu et al., 2007; Okada et al., 2009). Units of enzyme activities for tissue microsomes and recombinant P450
proteins are nmol/min/mg protein and nmol/min/nmol of P450, respectively. Units of Vmax/Km for tissue microsomes and recombinant P450 proteins are ml/min/nmol and ml/min/mg protein,
respectively. The units of Km and Ks values are mM.
Enzyme Source
Midazolam 19-Hydroxylation Midazolam 4- hydroxylation
Km Vmax Vmax/Km KS Km Vmax Vmax/Km KS
Microsomes
Marmoset liver 8.1 6 0.5 6.0 6 0.1 0.74 640 6 50 37 6 2 1.5 6 0.1 0.041 —
Cynomolgus monkey liver 15 6 1 5.0 6 0.1 0.33 2200 6 60 67 6 4 4.2 6 0.1 0.063 —
Human liver 6.6 6 0.4 2.5 6 0.1 0.38 1300 6 130 64 6 3 1.1 6 0.1 0.017 —
Marmoset small intestine 6.6 6 0.5 1.7 6 0.1 0.26 3200 6 820 33 6 6 0.35 6 0.02 0.011 —
Cynomolgus monkey small intestine 7.0 6 0.2 2.1 6 0.1 0.30 — 39 6 1 1.4 6 0.1 0.036 —
Human small intestine 1.7 6 0.1 0.88 6 0.01 0.52 930 6 68 27 6 2 0.34 6 0.01 0.013 —
Recombinant P450
Marmoset 3A4 ortholog 2.5 6 0.4 35 6 1 14 710 6 150 21 6 2 25 6 1 1.2 —
Marmoset 3A5 ortholog 170 6 44 3.7 6 0.4 0.020 — 190 6 21 4.7 6 0.2 0.025 —
Marmoset 3A90 34 6 1 16 6 1 2000 6 100 310 6 21 3.4 6 0.1 0.011 —
Cynomolgus monkey 3A4 2.5 6 0.2 21 6 1 8.4 600 6 79 16 6 1 40 6 1 2.5 1200 6 100
Cynomolgus monkey 3A5 3.2 6 0.5 28 6 1 8.8 1900 6 680 8.2 6 0.1 24 6 1 2.9 —
Human 3A4 1.7 6 0.2 12 6 1 7.1 660 6 100 25 6 3 8.6 6 0.5 0.32 2600 6 1100
Human 3A5 3.8 6 0.5 47 6 2 12 1900 6 560 30 6 2 5.9 6 0.1 0.20 —
TABLE 4
Kinetic parameters of nifedipine oxidation by recombinant P450 3A enzymes and tissue microsomes from marmosets,
cynomolgus monkeys, and humans
Kinetic parameters were determined by nonlinear regression analysis (mean 6 standard error, n = 12 points of substrate concentrations
of 1.1–200 mM) using the equation v = Vmax  [S]/(Km + [S]) for Michaelis-Menten or v = Vmax  [S]n/(S50 n + [S]n) for Hill equation
(Emoto et al., 2001; Okada et al., 2009). Units of enzyme activities for tissue microsomes and recombinant P450 proteins are nmol/min/mg
protein and nmol/min/nmol of P450, respectively. Units of Vmax/Km for tissue microsomes and recombinant P450 proteins are ml/min/nmol
and ml/min/mg protein, respectively. The units of Km and S50 values are mM.
Enzyme Source Km or S50 n
a Vmax Vmax/Km
Microsomes
Marmoset liver 42 6 1 — 10 6 1 0.24
Cynomolgus monkey liver 27 6 1 1.4 6 0.1 9.5 6 0.2 0.35
Human liver 17 6 1 1.1 6 0.1 4.2 6 0.1 0.25
Marmoset small intestine 84 6 6 1.3 6 0.1 2.2 6 0.1 0.026
Cynomolgus monkey small intestine 37 6 1 1.1 6 0.1 3.2 6 0.1 0.086
Human small intestine 24 6 2 1.1 6 0.1 2.6 6 0.1 0.11
P450
Marmoset 3A4 ortholog 33 6 4 — 77 6 3 2.3
Marmoset 3A5 ortholog 37 6 10 1.5 6 0.4 3.3 6 0.4 0.089
Marmoset 3A90 190 6 40 1.3 6 0.1 54 6 7 0.28
Cynomolgus monkey 3A4 31 6 5 — 94 6 5 3.0
Cynomolgus monkey 3A5 35 6 4 1.4 6 0.1 138 6 7 3.9
Human 3A4 52 6 2 1.6 6 0.1 123 6 2 2.4
Human 3A5 78 6 6 2.3 6 0.2 121 6 7 1.6
an represents the Hill coefficient.
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cynomolgus monkeys, great apes, and humans, and phylogenetically
had a close relationshipwith the human counterparts. P450 3A4 ortholog
mRNA was abundant in marmoset livers and small intestines among
three P450 3A mRNAs; P450 3A4 ortholog and 3A5 ortholog/3A90
proteins were also detected in these organs contributing to drug metab-
olism. Recombinant P450 3A4 ortholog, 3A5 ortholog, and 3A90
enzymes prepared in E. coli membranes catalyzed typical human P450
3A probe substrates, suggesting that P450 3A function was highly
conserved between marmosets and humans. The significant correlation
relationship between P450 3A4 ortholog contents and midazolam
19-hydroxylation activities in marmoset livers showed that the P450
3A4 ortholog enzyme greatly contributed tomidazolam 19-hydroxylation
in marmoset liver microsomes. These results indicated that marmoset
P450 3A forms have functional similarities with those of humans in terms
of tissue expression and enzymatic properties.
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